·A GPRC5D targeting CAR-T for relapsed or refractory MM with promising clinical results, presented at 2022 ASCO and EHA
·Received FDA IND Approval in Jan 2023
·Received NMPA IND Approval in Aug 2023
·Received FDA Orphan Drug Designation in Oct 2022
·Follow-up data published on The Lancet Haematology